HomeCompareRSNVF vs ABBV

RSNVF vs ABBV: Dividend Comparison 2026

RSNVF yields 2197.80% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RSNVF wins by $23989303722.51M in total portfolio value
10 years
RSNVF
RSNVF
● Live price
2197.80%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23989303722.61M
Annual income
$22,018,526,951,961,570.00
Full RSNVF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — RSNVF vs ABBV

📍 RSNVF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRSNVFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RSNVF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RSNVF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RSNVF
Annual income on $10K today (after 15% tax)
$186,813.19/yr
After 10yr DRIP, annual income (after tax)
$18,715,747,909,167,332.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, RSNVF beats the other by $18,715,747,909,146,276.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RSNVF + ABBV for your $10,000?

RSNVF: 50%ABBV: 50%
100% ABBV50/50100% RSNVF
Portfolio after 10yr
$11994651861.36M
Annual income
$11,009,263,475,993,170.00/yr
Blended yield
91.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

RSNVF
No analyst data
Altman Z
12.4
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RSNVF buys
0
ABBV buys
0
No recent congressional trades found for RSNVF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRSNVFABBV
Forward yield2197.80%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$23989303722.61M$102.3K
Annual income after 10y$22,018,526,951,961,570.00$24,771.77
Total dividends collected$23850400133.48M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RSNVF vs ABBV ($10,000, DRIP)

YearRSNVF PortfolioRSNVF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$230,480$219,780.22$11,550$430.00+$218.9KRSNVF
2$4,980,725$4,734,111.53$13,472$627.96+$4.97MRSNVF
3$100,941,649$95,612,273.14$15,906$926.08+$100.93MRSNVF
4$1,918,962,598$1,810,955,032.86$19,071$1,382.55+$1918.94MRSNVF
5$34,228,397,184$32,175,107,204.38$23,302$2,095.81+$34228.37MRSNVF
6$572,984,256,150$536,359,871,163.32$29,150$3,237.93+$572984.23MRSNVF
7$9,004,381,142,099$8,391,287,988,018.40$37,536$5,121.41+$9004381.10MRSNVF
8$132,875,919,296,168$123,241,231,474,122.23$50,079$8,338.38+$132875919.25MRSNVF
9$1,841,847,449,203,363$1,699,670,215,556,462.80$69,753$14,065.80+$1841847449.13MRSNVF
10$23,989,303,722,609,170$22,018,526,951,961,570.00$102,337$24,771.77+$23989303722.51MRSNVF

RSNVF vs ABBV: Complete Analysis 2026

RSNVFStock

Reyna Silver Corp. operates as a silver exploration company in Mexico. The company explores for silver and gold properties. Its flagship property is its 100% owned Guigui Property, which consists of 7 concessions covering an area of 4,553.7034 hectares located in Chihuahua, Mexico. Reyna Silver Corp. is based in Vancouver, Canada.

Full RSNVF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this RSNVF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RSNVF vs SCHDRSNVF vs JEPIRSNVF vs ORSNVF vs KORSNVF vs MAINRSNVF vs JNJRSNVF vs MRKRSNVF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.